Octreotide Acetate

CHEMBL1200480 Phase 4 معتمد Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1139.3 g/mol

LogP

—

Phase

4

A acetate salt form of octreotide with the same therapeutic properties. A synthetic somatostatin that suppresses hormone release from tumors, used for carcinoid tumors and acromegaly.

الوزن الجزيئي

1139,3000 g/mol

TPSA

457,00 Å²

المجالات العلاجية

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Migraine Non-Alcoholic Fatty Liver Disease Stroke Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Cardiovascular Disease Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(=O)O.C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O

InChI

InChI=1S/C49H66N10O10S2.C2H4O2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;1-2(3)4/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1H3,(H,3,4)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+;/m1./s1

Molecular Formula

C53H74N10O14S2

HBD / HBA

15 / 18

الروابط القابلة للدوران

17

الذرات الثقيلة

79

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A acetate salt form of octreotide with the same therapeutic properties. A synthetic somatostatin that suppresses hormone release from tumors, used for carcinoid tumors and acromegaly.

Yes, Octreotide Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200480. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 155804637. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Octreotide Acetate على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C53H74N10O14S2
المرادفات: 4

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.